In its latest quarterly update, Davion Healthcare announced an amendment to its global license agreement with NeuRX Health, pushing the start of license fee and royalty payments to July 2026. This adjustment aligns payments with the planned second-half 2026 commercial launch of BreastCheck, Davion's flagship non-invasive home test product utilizing patented thermographic technology. The company operates a capital-efficient licensing model leveraging third-party partners for manufacturing and commercialization, but remains pre-revenue and dependent on these licensees’ execution and regulatory compliance. Key growth drivers include upcoming market launches, regulatory approvals, and potential new license agreements for additional products. Operational risks center on licensee performance and cash flow timing.